We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Edwards Lifesciences Corp | NYSE:EW | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
3.70 | 4.28% | 90.16 | 90.37 | 86.79 | 87.23 | 3,111,297 | 01:00:00 |
IRVINE, Calif., Nov. 1, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $750 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $1.7 billion of shares in 2022.
Under the terms of this ASR, Edwards will receive an initial delivery of approximately 8 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be based on the volume weighted average share price during the term of the agreement. The company is funding the share repurchase under the ASR with its existing cash.
Following this repurchase, Edwards has approximately $900 million remaining in its share repurchase authorization approved by its Board of Directors.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edwards-lifesciences-announces-750-million-accelerated-share-repurchase-301664547.html
SOURCE Edwards Lifesciences Corporation
Copyright 2022 PR Newswire
1 Year Edwards Lifesciences Chart |
1 Month Edwards Lifesciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions